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Canadaa b s t r a c t
Long term control of rubella and congenital rubella syndrome relies on high population-level immunity
against rubella, particularly among women of childbearing age. In Canada, all pregnant women should be
screened so that susceptible new mothers can be offered vaccination for rubella before discharge. This
study was undertaken to estimate rubella susceptibility in a cohort of pregnant women in Canada and
to identify associated socio-economic and demographic factors. Biobanked plasma samples were
obtained from the Maternal-Infant Research on Environmental Chemicals (MIREC) study, in which preg-
nant women were recruited between 2008 and 2011. Socio-demographic characteristics and obstetric
histories were collected. Second trimester plasma samples (n = 1,752) were tested for rubella-specific
IgG using an in-house enzyme-linked immunosorbent assay. The percentage of women with IgG titers
<5 IU/mL, 5–10 IU/mL, and 10 IU/mL were 2.3%, 10.1%, and 87.6%, respectively. Rates of seronegativity,
defined as <5 IU/mL, were 3.1% in women who had no previous live birth and 1.6% in women who had
given birth previously. Among the latter group, seronegativity was higher in women with high school
education or less (adjusted OR (aOR) 5.93, 95% CI 2.08–16.96) or with a college or trade school diploma
(aOR 3.82, 95% CI 1.45–10.12), compared to university graduates, and those born outside Canada (aOR
2.60, 95% CI 1.07–6.31). In conclusion, a large majority of pregnant women were found to be immune
to rubella. Further research is needed to understand inequalities in vaccine uptake or access, and more
effort is needed to promote catch-up measles-mumps-rubella vaccination among socioeconomically dis-
advantaged and immigrant women of childbearing age.
Crown Copyright  2017 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Rubella, one of the classic childhood exanthems, is caused by
rubella virus, a positive-sense, single-stranded RNA virus of the
Togaviridae family [1–3]. In children, the disease is characterized
by a self-limiting rash and fever. Up to 50% of infections are sub-
clinical [4]. Complications such as meningoencephalitis, thrombo-
cytopenia and post-infectious encephalomyelitis occur but are very
rare [1]. In adults and particularly in post-pubertal women, rubella
infection is an important cause of arthralgia/arthritis [3]. The most
severe complications of rubella in adult women occur during preg-
nancy when infection can lead to miscarriage, stillbirth, or congen-ital rubella syndrome (CRS), a constellation of congenital
anomalies including microphthalmia and other eye defects, sen-
sorineural deafness, heart defects, and brain damage such as
microcephaly [1]. The rate of vertical transmission and CRS is high-
est when maternal infection occurs in the first ten weeks of preg-
nancy and decreases afterwards [2].
In Canada, routine vaccination with rubella-containing vaccine
has been publicly-funded in most provinces since the 1970s, and
by 1983 a combined measles-mumps-rubella vaccine (MMR) was
incorporated into all provincial and territorial routine vaccination
programs. As a result, the average annual incidence of rubella fell
from 18.9 cases per 100,000 in 1979–1983 to 5.0 cases per
100,000 in 1984–1997 [5]. In parallel, the rate of CRS fell from
3.0 cases per 100,000 live births in 1979–1983 to 0.8 cases per
100,000 live births in 1984–1997 [5]. After the introduction of a
second dose of MMR vaccine into all provincial and territorial
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rubella and CRS incidence rates decreased further to 0.1 cases per
100,000 and 0.2 cases per 100,000 live births in 1998–2008,
respectively [5]. Canada achieved elimination of both rubella and
CRS by 2005, with an annual average of only 4.3 rubella cases
reported per year between 2006 and 2011 and no reported cases
of CRS due to exposure in Canada since 2000 [5,6].
The long-term control of rubella and CRS relies on maintaining
high coverage with a rubella-containing vaccine. Seroconversion
after a single dose of live attenuated rubella vaccines, including
MMR, have consistently exceeded 95% [7] and vaccine-induced
anti-rubella titres can be remarkably robust [8]. Nonetheless, anti-
body titres tend to fall after vaccination [9] and at least some of
those who have been previously vaccinated mount primary
responses upon revaccination [10]. Although global inclusion of a
rubella-containing vaccine in routine childhood vaccination pro-
grams has increased steadily in the last two decades, vaccination
programs in one third of the world’s low- and middle-income
countries did not include a rubella-containing vaccine in 2009
[11]. Of all World Health Organization (WHO) Regions, only the
Americas have interrupted the endemic transmission of rubella
so far [1]. Finally, widely publicized and fraudulent claims linking
MMR vaccination to autism [12] may have negatively affected vac-
cine uptake, though their actual impact remains difficult to mea-
sure. All of these factors highlight the need to maintain high
vaccination coverage.
As CRS is a severe consequence of rubella infection during preg-
nancy, rubella immunity in post-pubertal women is of particular
interest. The Society of Obstetricians and Gynaecologists of Canada
(SOGC) recommends that (i) every opportunity be taken to assess
rubella immunity in women of childbearing age (e.g., pre-
conception consultation); (ii) all pregnant women be screened to
determine their rubella serostatus; and (iii) susceptible women
be immunized either pre-conception or post-partum before hospi-
tal discharge [13]. While rubella seroprevalence studies have pre-
viously been conducted in Canada, they focussed on specific
provinces and lacked detailed information on risk factors for
rubella susceptibility. Moreover, although screening studies on
pregnant women conducted in Ontario [14] and Alberta [15] iden-
tified those tested more than once for rubella IgG during the study
period, neither could distinguish women who had at least one pre-
vious live birth from those who had not. Knowing the seropreva-
lence of rubella antibodies among women who have had a
previous live birth is of particular importance, as it provides a
proxy for compliance with recommendations to screen pregnant
women and to immunize at-risk mothers post-partum.
This study was undertaken to (i) determine the seroprevalence
of rubella IgG antibodies in a cohort of pregnant women in Canada
(overall, for those who had no previous live birth, and for those
who had at least one); and (ii) to identify the socio-economic
and demographic factors associated with higher susceptibility to
rubella infection.2. Methods
2.1. The MIREC study
The Maternal-Infant Research on Environmental Chemicals
(MIREC) study was undertaken to examine potential adverse
health effects of prenatal exposure to specific environmental
chemicals on pregnancy and infant health. The study participants
were pregnant women recruited during their first trimester
between 2008 and 2011 in ten Canadian cities within six provinces
(British Columbia, Alberta, Manitoba, Ontario, Québec, and Nova
Scotia) [16]. Enrolment occurred between the 6th and 13th weekof pregnancy, at which time participants completed a question-
naire documenting their socio-demographic characteristics and
obstetrical history. Maternal blood samples were collected in each
trimester and at delivery. Plasma from the second trimester were
used in this study because of their availability in the biobank. Sam-
ples were centrifuged within two hours of collection, aliquoted,
and stored at 20 C until tested.
2.2. Laboratory methods
Plasma samples were tested for rubella-specific IgG using an in-
house enzyme-linked immunosorbent assay (IH-EIA) based upon a
highly purified GMP-quality rubella virus lysate antigen (Rubella
K2S: Microbix, Mississauga, ON). Briefly, 96-well microtiter
round-bottom plates (Greiner bio-one, Monroe, NC) were coated
overnight with 50 lL of rubella virus antigen at a concentration
of 0.25 lg/well in a carbonate buffer (pH 9.6) at 4 C. After washing
three times in PBS-T (phosphate-buffered saline [pH 7.4] contain-
ing 0.05% [vol/vol] Tween 20), 300 lL of blocking buffer (ELISA
Blocker Blocking Buffer – Thermofisher Scientific, Ottawa, ON)
was added per well, and the reaction mixture was incubated for
two hours at room temperature to block nonspecific binding. Plates
were washed three times with PBS-T, and then 10 lL of control or
sample was diluted in 240 lL of blocking buffer, added to each well
and incubated at 37 C for one hour. After washing three times
with PBS-T, 100 lL of mouse anti-human IgG conjugated to horse-
radish peroxidase (Fisher Scientific, Ottawa, ON) diluted 1:50,000
in blocking buffer was added to each well, and the reaction mixture
was incubated for one hour at 37 C. After washing four times,
100 lL of substrate, 3,30,5,50-tetramethylbenzadine was added to
each well, and the reaction mixture was incubated in the dark at
room temperature for 20 min. The reaction was stopped with the
addition of 50 lL of 5% sulfuric acid. The optical density of each
control and sample was read at 450 nm.
Each microtiter plate contained a 7-point standard curve con-
structed using duplicate, serial 2-fold dilutions of the WHO RUBI-
1-94 starting at a concentration of 40 IU/mL (range 40–0.625 IU/
mL). An internal anti-rubella virus IgG quality control sample
diluted with negative human serum to 20 IU/mL (based on the
Architect assay: Abbott Diagnostics, Abbott Park, IL) was tested
at least once in each plate.
In preliminary work to optimize the IH-EIA, variance between
duplicate wells was less than 15% and inter-assay variance was
23%. The IH-EIA was validated essentially as described by Dimech
et al. [17] against a commercial EIA (Architect: Abbott Diagnostics)
using a panel of human sera and the WHO international anti-
rubella immunoglobulin standard (RUBI-1-94). The Architect assay
is a micro-particle chemiluminescent enzyme immune-assay that
is FDA-approved for clinical diagnostic use. A total of 126 samples,
including 33 with IgG titers <10 IU/mL, were analysed in both
assays and the ability of IH-EIA to detect sero-negative samples
was compared to the commercial platform. Overall, the positive
and negative percent agreements between the two assays were
86% and 92% respectively, and the negative and positive predictive
values were 82% and 94% respectively.
2.3. Data analysis
Data were analysed using SAS Enterprise Guide 5.1. Participant
year of birth was categorized as follows: those born from 1983
onwards (i.e. after the initiation of MMR vaccination at 12 months
of age in Canada), those born between 1978 and 1982, those born
between 1974 and 1977, and those born between 1960 and 1973.
The distribution of anti-rubella IgG titers was assessed as one of
three categories: rubella susceptible/seronegative (<5 IU/mL),
indeterminate susceptibility (5 to <10 IU/mL), and rubella
Table 1
Socio-demographic characteristics and birth history of MIREC study participants with
a second-trimester plasma sample available for testing (n = 1,752).
Characteristic n %
Province of residence
















High school or less 232 13.2
College or trade school diploma 403 23.0
University graduate 1,115 63.6
Not stated 2 0.1
Household Income
$1 - $60,000 371 22.1
$60,001 - $100,000 620 36.9
$100,001 or more 689 41.0
Not stated 72 4.3
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titers with their 95% confidence intervals were calculated by birth
year categories, and compared using generalized linear models
(GLM). This analysis was repeated after excluding women who
had had a previous live birth (to prevent effect modification by
post-partum vaccination) and women born outside Canada (to
examine the effect of MMR introduction).
For the analysis of factors associated with rubella susceptibility,
the threshold of <5 IU/mL suggested by Lai et al. [15] was used to
identify those who were definitively seronegative. In contrast, the
use of a higher threshold (i.e. <10 IU/mL) to identify all those who
may not be immune is clinically appropriate [18] as they could ben-
efit from vaccination.
Associations between sociodemographic factors and rubella
seronegativity were determined by simple and multiple logistic
regressions. Factors with p values below 0.10 in simple regressions
were included in multiple regression models and retained in mod-
els as long as their p values remained below 0.10. The standard
errors of parameter estimates in the multiple regression models
were compared to those in the simple regression models to find
co-linearity, but none were identified. Unadjusted odds ratios
(OR) and adjusted odds ratios (aOR) and their respective 95% con-
fidence intervals were calculated. This analysis was carried out for
the entire study population, and then separately for women who
had no previous live births and those who had at least one live




Number of previous live births
0 781 44.6
1 704 40.2
2 267 15.22.4. Ethics
This study was reviewed and approved by Health Canada and
the Public Health Agency of Canada’s Research Ethics Board (REB).
The MIREC study had previously been reviewed and approved
by the REBs of the Centre Hospitalier Universitaire Sainte-Justine,
all recruitment sites and Health Canada and Public Health Agency
of Canada. The consent provided by participants allowed for the
use of anonymized data and bio-banked biological samples for fur-
ther research.3. Results
Of the 1,928 participants enrolled in the MIREC study, 1,752 had
a second-trimester plasma sample available for testing. Their age
at enrollment ranged between 18 and 48 years, 64% of them were
university graduates, and 55% had had at least one previous live
birth (Table 1).
Anti-rubella IgG antibody titers in the second trimester of preg-
nancy ranged from 0.9 to 897 IU/mL. The percentage of women
with IgG titers <5 IU/mL, between 5 and 10 IU/mL, and 10 IU/
mL were 2.3%, 10.1%, and 87.6%, respectively (Table 2).
Anti-rubella IgG antibody titers were lower in younger partici-
pants (Table 3), with the greatest gap between those born in
1974–1977 compared to those born in 1978–1982. Similar trends
were observed after excluding women who had had at least one
live birth (i.e., potentially vaccinated post-partum) and those born
outside Canada (i.e., possibly vaccinated according to a different
schedule or not vaccinated at all). There was no significant differ-
ence between those born on or after 1983 and those born immedi-
ately before that milestone (Table 3).
Adjusting for year of birth, education, and history of previous
live birth, the odds of rubella seronegativity were significantly (i)
lower in women born in 1978–1982 compared to those born in
1960–1973 (aOR 0.35, 95% CI 0.14–0.90), (ii) higher in women with
a trade school or college diploma compared to university graduates
(aOR 2.15, 95% CI 1.03–4.51), and (iii) higher in women with one ormore live births compared with those with none (aOR 0.47, 95% CI
0.24–0.92) (Table 4). Among those who had had no previous live
births (and therefore no opportunity for postpartum vaccination),
the odds of rubella susceptibility were even greater for those with
(i) a high school education or less [5.93 (2.08–16.96)] or (ii) a col-
lege or trade school diploma [3.82 (1.45–10.12)] compared to uni-
versity graduates. Similarly, the association between being born
outside Canada and the risk of rubella seronegativity was statisti-
cally significant in women with no previous live births, whereas
it was non-significant for the entire population (Table 5). In
women who had had a previous live birth, none of the demo-
graphic factors analysed were associated with rubella seronegativ-
ity (Table 6).4. Discussion
Plasma concentrations of anti-rubella IgG in pregnant women
were clearly lower in those born after the introduction of monova-
lent (early 1970s) and subsequently combined rubella-containing
vaccines (i.e. MMR, 1983). This trend is consistent with decreased
circulation of wild-type rubella virus in Canada following vaccine
introduction [5]. A similar pattern has been observed in countries
as diverse as Spain [19] and Peru [20]. As higher vaccination rates
are achieved and fewer exposures to wild-type virus occur, popu-
lations are increasingly dependent upon vaccine-induced immu-
nity alone. Even though rubella-containing vaccines are highly
immunogenic, they generally produce a lower and less durable
antibody response than natural infection [21]. To date however,
decreasing antibody levels in highly vaccinated populations have
Table 2
Distribution of anti-rubella IgG titers in pregnant women by history of live birth.
Rubella IgG titers (IU/mL) All participating women
(n = 1,752)
Women with no previous live
birth (n = 781)
Women with 1 previous live
birth (n = 971)
n % (95% CI) n % (95% CI) n % (95% CI)
0–4.99 40 2.3 (1.6–3.1) 24 3.1 (2.0–4.5) 16 1.6 (0.9–2.7)
5.00–9.99 177 10.1 (8.7–11.6) 90 11.5 (9.4–14.0) 87 9.0 (7.2–10.9)
10.00 1535 87.6 (86.0–89.1) 667 85.4 (82.7–87.8) 868 89.4 (87.3–91.3)
Table 3
Participant anti-rubella IgG titers (IU/mL) by birth year, live birth history, and place of birth.
Year of birth All participating women (n = 1,752) Women with no previous live birth (n = 781) Canadian-born women with no previous live
birth (n = 640)
N Geometric mean (95% CI) p N Geometric mean (95% CI) p N Geometric mean (95% CI) p
1960–1973 470 30.3 (27.9–33.0) Reference 167 30.1 (26.2–34.7) Reference 121 29.7 (25.4–34.8) Reference
1974–1977 478 29.0 (26.8–31.2) 0.4097 170 26.7 (23.5–30.3) 0.2052 131 24.9 (21.7–28.6) 0.0908
1978–1982 581 23.8 (22.3–25.4) <0.0001 308 22.9 (20.9–25.2) 0.0012 264 21.8 (19.8–24.0) 0.0006
1983–1992 223 22.9 (20.4–25.8) <0.0001 136 21.4 (18.2–25.1) 0.0007 124 20.4 (17.5–23.7) 0.0004
p values are for the comparison with the 1960–1973 birth cohort.
Table 4
Determinants of rubella IgG seronegativitya in participants (n = 1,752).
Characteristic N n % Unadjusted OR (95% CI) Adjustedb OR (95% CI)
Year of birth
1960–1973 470 13 2.8 Reference Reference
1974–1977 478 10 2.1 0.75 (0.33–1.73) 0.76 (0.33–1.77)
1978–1982 581 7 1.2 0.43 (0.17–1.08) 0.35 (0.14–0.90)
1983–1992 223 10 4.5 1.65 (0.71–3.82) 0.98 (0.39–2.47)
Education
High school or less 232 9 3.9 2.46 (1.09–5.55) 2.38 (0.97–5.84)
College or trade school diploma 403 13 3.2 2.03 (0.99–4.19) 2.15 (1.03–4.51)
University graduate 1,115 18 1.6 Reference Reference
Not stated 2 0 0.0
Household Income
$1 - $60,000 371 12 3.2 2.06 (0.90–4.72)
$60,001 - $100,000 620 13 2.1 1.32 (0.59–2.97)
$100,001 or more 689 11 1.6
Not stated 72 4 5.6 3.63 (1.12–11.70)
Born outside Canada
No 1,425 29 2.0 Reference
Yes 327 11 3.4 1.68 (0.83–3.39)
Previous live birth
No 781 24 3.1 Reference Reference
Yes 971 16 1.6 0.53 (0.28–1.00) 0.47 (0.24–0.92)
a Seronegativity defined as IgG titers <5 IU/mL.
b Model includes all variables for which values are shown in the column.
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CRS [22].
The overall percent of pregnant women immune to rubella in
this study (88% with 10 IU/mL) was lower than the 90% mea-
sured in Ontario pregnant women in 2006–2010 [14], but higher
than the 84.1% measured in Alberta in 2009–2012 [15]. Rubella
seropositivity in our study was also slightly lower than the
91.5% measured in the United States in non-pregnant women
aged 20–49 [23]. The different assays used in these studies may
have influenced rubella seroprevalence results, particularly at
low antibody titers [17]. Nonetheless, all of these studies send
the same message: that some women of child-bearing age may
be susceptible to rubella.
Although not truly national in scope, our rubella seroprevalence
study is the first to be conducted across multiple Canadian pro-
vinces representing 92.5% of the country’s total population in
2016 [24] and with good geographic coverage.Unfortunately, the number of foreign-born women in this study
(total 327, seronegative 11) was too small to undertake a detailed
analysis by country or region of birth as the numbers of women
from specific regions would not allow valid inferences. However,
because of varying rubella vaccination programs and disease inci-
dence rates, differences between countries or regions of birth can
be expected. The SOGC recommends vaccinating all immigrant
and refugee women at their first encounter with the Canadian
health care system, unless they have documentation of effective
vaccination or natural immunity [13]. A chart review of 1,987
Canadian-born and 3,796 foreign-born pregnant women found
that, among the latter, those born in the Middle East or in North
Africa were at higher risk of seronegativity than those Canadian-
born, while those born in Sub-Saharan Africa were at lower risk.
Women from other parts of the world were not statistically differ-
ent from those Canadian-born [25]. In a study of 1,480 immigrants
in Montreal, rubella seronegativity rates (<10 IU/mL) ranged from
Table 5
Determinants of rubella IgG seronegativitya in participants who had no previous live birth (n = 781).
Characteristic N % Unadjusted OR (95% CI) Adjustedb OR (95% CI)
Year of birth
1960–1973 167 3.6 Reference
1974–1977 170 2.4 0.65 (0.18–2.33)
1978–1982 308 1.6 0.44 (0.13–1.47)
1983–1992 136 6.6 1.90 (0.66–5.48)
Education
High school or less 90 7.8 5.47 (1.93–15.49) 5.93 (2.08–16.96)
College or trade school diploma 164 5.5 3.77 (1.43–9.93) 3.82 (1.45–10.12)
University graduate 527 1.5 Reference Reference
Household Income
$1 - $60,000 170 5.3 3.41 (1.12–10.34)
$60,001 - $100,000 272 2.2 1.38 (0.42–4.56)
$100,001 or more 310 1.6
Not stated 29 13.8 9.76 (2.46–38.66)
Born outside Canada
No 640 2.5 Reference Reference
Yes 141 5.7 2.35 (0.98–5.60) 2.60 (1.07–6.31)
a Seronegativity defined as IgG titers <5 IU/mL.
b Model includes all variables for which values are shown in the column.
Table 6
Determinants of rubella IgG seronegativitya in participants who had at least one previous live birth (n = 971).
Characteristic N n % Unadjusted OR (95% CI)
Year of birth
1960–1973 303 7 2.3 Reference
1974–1977 308 6 1.9 0.84 (0.28–2.53)
1978–1982 273 2 0.7 0.31 (0.06–1.52)
1983–1992 87 1 1.1 0.49 (0.06–4.05)
Education
High school or less 142 2 1.4 0.83 (0.18–3.81)
College or trade school diploma 239 4 1.7 0.98 (0.31–3.17)
University graduate 588 10 1.7 Reference
Not stated 2 0 0.0
Household Income
$1 - $60,000 201 3 1.5 0.94 (0.23–3.81)
$60,001 - $100,000 348 7 2.0 1.28 (0.43–3.84)
$100,001 or more 379 6 1.6 Reference
Not stated 43 0 0.0
Born outside Canada
No 785 13 1.7 Reference
Yes 186 3 1.6 0.97 (0.28–3.45)
a Seronegativity defined as IgG titers <5 IU/mL.
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in Sub-Saharan Africa immigrants and the highest in those born in
East Asia-Pacific countries [26]. These observations, together with
our current findings, reinforce the message that more effort is
needed to deliver catch-up vaccinations in immigrant women.
The association between lower educational attainment and
increased rubella susceptibility may suggest socio-economic
inequalities in rubella vaccine uptake. This possibility is consistent
with inequalities observed in the general uptake of childhood vac-
cines in Canada [27]. More research is needed to determine the
underlying causes of these inequalities, and to measure the relative
contributions of vaccine hesitancy and systemic barriers.
Little is currently known regarding either the completeness of
pre-natal screening or the uptake of postpartum rubella vaccina-
tion in Canada. In the 1990s, a chart review of prenatal rubella
screening and its follow-up in 2,551 women who delivered in
Québec hospitals found that among the 1.6% initially found to
be seronegative, 33.5% were definitely vaccinated post-partum,
29.5% were definitely not vaccinated, and vaccination was not
required for various reasons for 6%. The vaccination status ofthe remaining 31% could not be ascertained from the charts
[28]. In the absence of more recent published data, it is unknown
whether compliance with this health intervention changed over
time. However, the difference in seronegativity rates in the cur-
rent study between the women who had had a previous live birth
and those who had not (1.6% versus 3.1% respectively) suggest
that, while clearly not functioning optimally, the SOGC recom-
mendation to vaccinate post-partum is having at least some
impact.
This study has several limitations. MIREC was not designed to
study vaccination or vaccine-preventable diseases so the vaccina-
tion history of participants was not recorded. Moreover, the study
sample is not fully representative of the Canadian population as it
is primarily a convenience sample, and was restricted to six out of
ten provinces with no representation from the three territories.
Further, the proportion of university graduates in this study, 64%,
was much higher than the 35% measured in new mothers in a
population-based survey conducted in 2006–2007 [29]. Therefore,
the rates derived from our data may not be generalizable to all
pregnant women in Canada.
N.L. Gilbert et al. / Vaccine 35 (2017) 3050–3055 30555. Conclusion
Despite a general decrease over time in anti-rubella IgG titers
after the introduction of rubella-containing vaccines, a large
majority of pregnant women in the cohort were found to be
immune to rubella. Among those who had at least one previous
live birth, very few were susceptible to infection suggesting that
post-partum vaccination recommendations, while not fully com-
plied with, are having a positive impact. Lower educational attain-
ment (possibly an indicator of low socio-economic status) and
birth outside Canada were risk factors for rubella susceptibility.
Further research is warranted to understand the socioeconomic
inequalities in vaccine uptake or access, and more effort is needed
to promote catch-up MMR vaccination among socioeconomically
disadvantaged and immigrant women of childbearing age.
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